What liver monitoring is needed with tigecycline use?

With tigecycline, liver monitoring is typically recommended because the drug can cause transaminase elevations and, less commonly, more serious hepatotoxicity.

What to monitor

• Baseline liver tests before starting:
  • AST and ALT
  • Alkaline phosphatase (ALP)
  • Total bilirubin
• Ongoing monitoring during therapy (especially if treatment is prolonged or the patient has underlying liver disease):
  • Repeat AST/ALT and bilirubin at regular intervals (commonly at least weekly, and more often if abnormalities develop or risk is high).

When to be more cautious / consider holding or reassessing

• If AST/ALT rise significantly (e.g., several-fold above baseline) or
• If bilirubin increases (suggesting a cholestatic/hepatocellular injury pattern) or
• If the patient develops signs/symptoms of liver injury (jaundice, dark urine, pruritus, RUQ pain, unexplained fatigue, nausea/vomiting).

Practical note

• Dose adjustment for hepatic impairment may be needed (tigecycline has guidance for moderate to severe hepatic impairment), so the baseline labs and trend matter.

If you tell me the patient’s current LFT values, planned duration, and whether there’s existing liver disease, I can suggest a more specific monitoring frequency and what thresholds are typically used clinically.